Joseph Paul Eder, MD

Professor of Medicine (Medical Oncology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale

Medical Oncology: Early Drug Development Program | Subset Medical Oncology Faculty

Yale Medical Group

Clinical Trials

Conditions Study Title
Colon E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Colon 19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the colon
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, Soft Tissue, Stomach A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Bladder, Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, Other Female Genital, Other Skin, Ovary, Pancreas A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
Breast - Female, Kaposi's sarcoma, Lung, Melanoma, skin, Ovary, Soft Tissue A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Unknown Sites Tumor Molecular Profiling
Breast - Female, Lung, Ovary An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination with Gemcitabine in Patients with Refractory Solid Tumors or Lymphoma
Bladder, Colon, Lip, Oral Cavity and Pharynx, Lung A Phase 1 Study of MEDI6383 (an OX40 Agonist) in Adult Subjects with Select Advanced Solid Tumors
Bladder, Breast - Female, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Pancreas, Soft Tissue, Stomach A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Part A: A Dose-Escalation Study in Patients with Advanced Solid Tumors Part B: An Expansion Cohort in Patients with Selected Malignancies
Colon, Lung A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A AND COBIMETINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCERS WITH MUTANT KRAS
Kidney, Melanoma, skin A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects with Advanced Malignancies
Breast - Female, Lung, Pancreas A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS
Breast - Female, Esophagus, Eye and Orbit, Larynx, Lip, Oral Cavity and Pharynx An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of oral BAY 1161909 in combination with weekly intravenous paclitaxel given in an intermittent dosing schedule in subjects with advanced malignancies
Colon, Lung, Melanoma, skin, Pancreas PHASE 1A MULTICENTER, OPEN-LABEL SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF CC-90003, A SELECTIVE EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) INHIBITOR, IN SUBJECTS WITH LOCALLY-ADVANCED OR METASTATIC, RELAPSED, OR REFRACTORY BRAFV600 OR RAS-MUTATED MALIGNANCIES
Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0994 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Breast - Female, Colon, Hodgkin's Lymphoma, Lung, Melanoma, skin, Non-Hodgkin's Lymphoma, Ovary, Prostate An Open-Label, Dose-escalation/expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma

Edit this profile

Contact Info

Joseph Paul Eder, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
Mailing Address
PO Box 208028
New Haven, CT 06520-8028

Curriculum Vitae